Poongjeon Pharmacy Co Ltd

Poongjeon Pharmacy Co Ltd has a liquidity position that is relatively strong, with a current ratio of 2.28, indicating the company can cover its short-term liabilities with its short-term assets. The company holds KRW 6,961,409,680 in cash and equivalents, which is a significant portion of its total assets of KRW 51,993,772,290. However, the company reported negative operating cash flow of KRW -5,303,086,020 and free cash flow of KRW -2,842,967,900, suggesting operational cash generation is under pressure. Profitability metrics for Poongjeon Pharmacy Co Ltd are mixed. The company reported a net income of KRW 202,502,790, but this was accompanied by an operating loss of KRW -2,668,415,260. Return on equity (ROE) is 0.56%, and return on assets (ROA) is 0.39%, both of which are below the industry median for biotechnology firms. The company's gross profit of KRW 4,407,051,240 represents 18.5% of its total revenue of KRW 23,839,029,790, which is in line with the industry average. The company's revenue is derived from multiple segments, including cell therapy products, cosmetics, and hair growth protein manufacturing. However, the financial snapshot does not provide a breakdown of revenue by segment or geography. Given the company's focus on cell therapy and cosmetics, it is likely that a significant portion of its revenue is concentrated in the domestic Korean market, though this is not explicitly stated in the available data. The company's growth trajectory appears to be mixed. While it has a strong cash position, the negative operating and free cash flows suggest that the company is not generating sufficient cash from operations to support growth. The company's capital expenditures of KRW -4,688,127,360 indicate a significant investment in infrastructure or expansion, but the negative sign suggests these expenditures are not yet generating positive returns. The outlook for the current fiscal year is not explicitly provided, but the company's financial performance suggests a cautious outlook. The risk assessment for Poongjeon Pharmacy Co Ltd indicates low liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, and its debt-to-equity ratio of 0.15 suggests a conservative capital structure. However, the company's negative operating cash flow and free cash flow could pose a risk to its liquidity position in the future. The dilution potential is also low, as the number of shares outstanding is the same for both basic and diluted shares. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company continues to focus on its core business of cell therapy and cosmetics, and there are no indications of major strategic shifts or new product launches in the latest financial data. The company's risk assessment does not highlight any recent events that would significantly impact its operations or financial performance.